Assessing the clinical impact of sodium-glucose cotransporter type 2 (SGLT2)- inhibitors in treating heart failure with reduced ejection fraction

Authors

Keywords:

heart failure with reduced ejection fraction (HFrEF), SGLT2-inhibitors, guideline-directed medical therapy (GDMT)

Abstract

Heart failure with reduced ejection fraction (HFrEF), often considered life-threatening, presents a significant risk to patient health. Guideline-directed medical therapy (GDMT), comprising a four-drug regimen, is currently widely recommended to optimise patient outcomes. This article seeks to elucidate the absolute benefits of SGLT2-inhibitors in the management of HFrEF and their integration into GDMT protocols.

Author Biographies

JA Ker, University of Pretoria

Emeritus Professor of Internal Medicine, Faculty of Health Sciences, University of Pretoria, South Africa

K Outhoff, University of Pretoria

Associate Professor, Department of Pharmacology, Faculty of Health Sciences, University of Pretoria, South Africa

Downloads

Published

2024-07-02

Issue

Vol. 5 No. 2 (2024)

Section

Review